| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial
|
Righini, Marc
|
|
2016
|
3 |
12 |
p. e556-e562
nvt p.
|
artikel
|
| 2 |
Association between delivery methods for red blood cell transfusion and the risk of venous thromboembolism: a longitudinal study
|
Rogers, Mary A M
|
|
2016
|
3 |
12 |
p. e563-e571
nvt p.
|
artikel
|
| 3 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial
|
Popat, Rakesh
|
|
2016
|
3 |
12 |
p. e572-e580
nvt p.
|
artikel
|
| 4 |
Low risk is not enough: the dilemma of calf vein thrombosis
|
Schellong, Sebastian M
|
|
2016
|
3 |
12 |
p. e548-e549
nvt p.
|
artikel
|
| 5 |
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
|
Soverini, Simona
|
|
2016
|
3 |
12 |
p. e554-e555
nvt p.
|
artikel
|
| 6 |
Panobinostat in multiple myeloma
|
Gertz, Morie A
|
|
2016
|
3 |
12 |
p. e552-e553
nvt p.
|
artikel
|
| 7 |
Risk of venous thromboembolism and delivery methods for red blood cell transfusion
|
Tan, Tze-Woei
|
|
2016
|
3 |
12 |
p. e550-e551
nvt p.
|
artikel
|
| 8 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
|
Cortes, Jorge E
|
|
2016
|
3 |
12 |
p. e581-e591
nvt p.
|
artikel
|
| 9 |
Updates on blood transfusion guidelines
|
The Lancet Haematology,
|
|
2016
|
3 |
12 |
p. e547-
1 p.
|
artikel
|
Tijdschrift beschrijving